Decrease of Replicative Capacity of HIV Isolates after Genotypic Guided Change of Therapy

L. Sarmati, E. Nicastri, M. Montano, L. Dori, A. R. Buonomini, G. D'Ettorre, F. Gatti, S. G. Parisi, V. Vallo, M. Andreonil

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

A longitudinal study of the replication capacity of HIV strains isolated from 18 patients failing highly active antiretroviral therapy (HAART) was undertaken at the time of genotypic guided change of therapy and after 12 months. Patients were divided in two groups according to the response to therapy: immune responders (12 patients with immune recovery defined as having more than 100 CD4 cells compared to baseline value), and failing patients (six patients without immune recovery). At enrolment no significant difference in terms of CD4 cell count and HIV plasma viremia was detected between the two groups. One year after change of therapy, all patients experienced a decrease in the replication capacity of HIV strains. The HIV replication capacity of the failing and of immune-responder patients decreased from 60% (range 14-96%) to 26.4% (range 0.4-74.5) and from 46.8% (range 15-98%) to 3.6% (range 0.1-26.8%), respectively. At month 12, the difference of HIV replication capacity between the two groups reached a statistical significance (P <0.03). After the change of therapy, an increase in the number of drug resistance mutations in the protease gene was detected in both groups with a higher prevalence of M361 mutation in immune responders. The HIV strains of patients failing HAART showed a progressive impaired replication capacity. The degree of the impairment in viral replication correlated with the viro-immunological discordant response to HAART and with the acquisition of new drug resistant mutations in the protease gene. In patients failing HAART, the impaired replication capacity of HIV strains could justify the persistence of an immune recovery.

Original languageEnglish
Pages (from-to)511-516
Number of pages6
JournalJournal of Medical Virology
Volume72
Issue number4
DOIs
Publication statusPublished - Apr 2004

Fingerprint

HIV
Highly Active Antiretroviral Therapy
Therapeutics
Mutation
Peptide Hydrolases
Viremia
CD4 Lymphocyte Count
Drug Resistance
Genes
Longitudinal Studies
Pharmaceutical Preparations

Keywords

  • HAART
  • HIV drug resistance
  • Replication capacity

ASJC Scopus subject areas

  • Virology

Cite this

Sarmati, L., Nicastri, E., Montano, M., Dori, L., Buonomini, A. R., D'Ettorre, G., ... Andreonil, M. (2004). Decrease of Replicative Capacity of HIV Isolates after Genotypic Guided Change of Therapy. Journal of Medical Virology, 72(4), 511-516. https://doi.org/10.1002/jmv.20030

Decrease of Replicative Capacity of HIV Isolates after Genotypic Guided Change of Therapy. / Sarmati, L.; Nicastri, E.; Montano, M.; Dori, L.; Buonomini, A. R.; D'Ettorre, G.; Gatti, F.; Parisi, S. G.; Vallo, V.; Andreonil, M.

In: Journal of Medical Virology, Vol. 72, No. 4, 04.2004, p. 511-516.

Research output: Contribution to journalArticle

Sarmati, L, Nicastri, E, Montano, M, Dori, L, Buonomini, AR, D'Ettorre, G, Gatti, F, Parisi, SG, Vallo, V & Andreonil, M 2004, 'Decrease of Replicative Capacity of HIV Isolates after Genotypic Guided Change of Therapy', Journal of Medical Virology, vol. 72, no. 4, pp. 511-516. https://doi.org/10.1002/jmv.20030
Sarmati, L. ; Nicastri, E. ; Montano, M. ; Dori, L. ; Buonomini, A. R. ; D'Ettorre, G. ; Gatti, F. ; Parisi, S. G. ; Vallo, V. ; Andreonil, M. / Decrease of Replicative Capacity of HIV Isolates after Genotypic Guided Change of Therapy. In: Journal of Medical Virology. 2004 ; Vol. 72, No. 4. pp. 511-516.
@article{e26e3e8703f74fabb4e9fcf3f363ab19,
title = "Decrease of Replicative Capacity of HIV Isolates after Genotypic Guided Change of Therapy",
abstract = "A longitudinal study of the replication capacity of HIV strains isolated from 18 patients failing highly active antiretroviral therapy (HAART) was undertaken at the time of genotypic guided change of therapy and after 12 months. Patients were divided in two groups according to the response to therapy: immune responders (12 patients with immune recovery defined as having more than 100 CD4 cells compared to baseline value), and failing patients (six patients without immune recovery). At enrolment no significant difference in terms of CD4 cell count and HIV plasma viremia was detected between the two groups. One year after change of therapy, all patients experienced a decrease in the replication capacity of HIV strains. The HIV replication capacity of the failing and of immune-responder patients decreased from 60{\%} (range 14-96{\%}) to 26.4{\%} (range 0.4-74.5) and from 46.8{\%} (range 15-98{\%}) to 3.6{\%} (range 0.1-26.8{\%}), respectively. At month 12, the difference of HIV replication capacity between the two groups reached a statistical significance (P <0.03). After the change of therapy, an increase in the number of drug resistance mutations in the protease gene was detected in both groups with a higher prevalence of M361 mutation in immune responders. The HIV strains of patients failing HAART showed a progressive impaired replication capacity. The degree of the impairment in viral replication correlated with the viro-immunological discordant response to HAART and with the acquisition of new drug resistant mutations in the protease gene. In patients failing HAART, the impaired replication capacity of HIV strains could justify the persistence of an immune recovery.",
keywords = "HAART, HIV drug resistance, Replication capacity",
author = "L. Sarmati and E. Nicastri and M. Montano and L. Dori and Buonomini, {A. R.} and G. D'Ettorre and F. Gatti and Parisi, {S. G.} and V. Vallo and M. Andreonil",
year = "2004",
month = "4",
doi = "10.1002/jmv.20030",
language = "English",
volume = "72",
pages = "511--516",
journal = "Journal of Medical Virology",
issn = "0146-6615",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Decrease of Replicative Capacity of HIV Isolates after Genotypic Guided Change of Therapy

AU - Sarmati, L.

AU - Nicastri, E.

AU - Montano, M.

AU - Dori, L.

AU - Buonomini, A. R.

AU - D'Ettorre, G.

AU - Gatti, F.

AU - Parisi, S. G.

AU - Vallo, V.

AU - Andreonil, M.

PY - 2004/4

Y1 - 2004/4

N2 - A longitudinal study of the replication capacity of HIV strains isolated from 18 patients failing highly active antiretroviral therapy (HAART) was undertaken at the time of genotypic guided change of therapy and after 12 months. Patients were divided in two groups according to the response to therapy: immune responders (12 patients with immune recovery defined as having more than 100 CD4 cells compared to baseline value), and failing patients (six patients without immune recovery). At enrolment no significant difference in terms of CD4 cell count and HIV plasma viremia was detected between the two groups. One year after change of therapy, all patients experienced a decrease in the replication capacity of HIV strains. The HIV replication capacity of the failing and of immune-responder patients decreased from 60% (range 14-96%) to 26.4% (range 0.4-74.5) and from 46.8% (range 15-98%) to 3.6% (range 0.1-26.8%), respectively. At month 12, the difference of HIV replication capacity between the two groups reached a statistical significance (P <0.03). After the change of therapy, an increase in the number of drug resistance mutations in the protease gene was detected in both groups with a higher prevalence of M361 mutation in immune responders. The HIV strains of patients failing HAART showed a progressive impaired replication capacity. The degree of the impairment in viral replication correlated with the viro-immunological discordant response to HAART and with the acquisition of new drug resistant mutations in the protease gene. In patients failing HAART, the impaired replication capacity of HIV strains could justify the persistence of an immune recovery.

AB - A longitudinal study of the replication capacity of HIV strains isolated from 18 patients failing highly active antiretroviral therapy (HAART) was undertaken at the time of genotypic guided change of therapy and after 12 months. Patients were divided in two groups according to the response to therapy: immune responders (12 patients with immune recovery defined as having more than 100 CD4 cells compared to baseline value), and failing patients (six patients without immune recovery). At enrolment no significant difference in terms of CD4 cell count and HIV plasma viremia was detected between the two groups. One year after change of therapy, all patients experienced a decrease in the replication capacity of HIV strains. The HIV replication capacity of the failing and of immune-responder patients decreased from 60% (range 14-96%) to 26.4% (range 0.4-74.5) and from 46.8% (range 15-98%) to 3.6% (range 0.1-26.8%), respectively. At month 12, the difference of HIV replication capacity between the two groups reached a statistical significance (P <0.03). After the change of therapy, an increase in the number of drug resistance mutations in the protease gene was detected in both groups with a higher prevalence of M361 mutation in immune responders. The HIV strains of patients failing HAART showed a progressive impaired replication capacity. The degree of the impairment in viral replication correlated with the viro-immunological discordant response to HAART and with the acquisition of new drug resistant mutations in the protease gene. In patients failing HAART, the impaired replication capacity of HIV strains could justify the persistence of an immune recovery.

KW - HAART

KW - HIV drug resistance

KW - Replication capacity

UR - http://www.scopus.com/inward/record.url?scp=10744223664&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744223664&partnerID=8YFLogxK

U2 - 10.1002/jmv.20030

DO - 10.1002/jmv.20030

M3 - Article

VL - 72

SP - 511

EP - 516

JO - Journal of Medical Virology

JF - Journal of Medical Virology

SN - 0146-6615

IS - 4

ER -